RESEARCH STATS
POOL
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
Interactions with Platform & by Email
PARTICIPANTS
Unique # Participated
VALIDATIONS
Responses Validated*
DATA ROOM
EXECUTIVE
CITATIONS
COMPANY
DISCUSSIONS
BRAND/PRODUCT
INSIGHTS
TOTAL
DATA STACK
*Clients have full access to our data room
DATE
SEP 2023
COMPANIES
249
TABLES
108
PAGES
573
EDITION
19
PRICE
USD 5600
CODE
MCP-1392
*Engagement stats are ongoing and dynamic
OUR EXPERT PANELS
Panelists are carefully chosen based on their domain expertise and market influence.
Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.
WHY PARTICIPATE?
Expertise to the Power of YOU!
- Collaborative Insights - Expand your deep domain insights from participants at competitive companies worldwide while you share your own!
- Global Acumen Alerts - Expand your intelligence on your areas of interest by enabling our “Email Alerts” feature drawing from other influencers’ project participation.
- Enterprise-wide Project Discounts - Discounts start @ 10% and build up as more participants support our ongoing projects in your space.
- Complimentary Copies - We highly recommend collaboration with your team to draw upon their geographical domain expertise. Our platform enables collaborative engagements with 10 peers. When you or any of your team members purchase the report, the entire team will receive complimentary copies with full stack access to our data and updates for one year.
- Annual Digital Subscription to one of the business publications or $100 value gift card - No Purchase Required! The lead participant will receive the digital subscription
- The Economist
- MIT Technology Review
- Harvard Business Review
Note - Offer is limited to one participant per company. Offer may be withdrawn at anytime without notice once our annual maximum participation of leading players is fulfilled. Offer by invitation only, to enterprise executives in from companies featured in the project ranked. If you’ve received our initation, you’re qualified! If not, you may check your eligibility by registering to join our Project Expert Panel. Typically you must be have a Marketing, Strategy, Product Management or Business Development, role as a CXO or VP or Director or Manager directly involved with the P&L of the products or services covered in the report. You must complete all modules in the Primary Research Data Simulator.
MARKETGLASS
BASIC
- $500/Month/User. Extra Users @ $100/Month/User
- Annual Prepaid Subscription
- Single-User
- 10,000 Data Room Credits/Month
- Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
- Use MarketGlassTM Data Templates For Your Own Enterprise Data to Build Bespoke Research Reports.
- My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
PREMIUM
- $1000/Month/User. Extra Users @ $100/Month/User
- Annual Prepaid Subscription
- One Research Project With One Complimentary Update/Year
- 10-User License
- 10-User Peer-to-Peer Collaborative Features
- 200 Domain Expert Insights (With Name, Company, and Date)
- 50,000 Data Room Credits
- Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
- Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
- Use Your Own Data and MarketGlassTM Data Room Content.
- My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
- Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges
ENTERPRISE
- $2500/Month/User. Extra Users @ $150/Month/User
- Annual Prepaid Subscription
- Four Research Projects With One Complimentary Update/Year
- 25-User License
- 25-User Peer-to-Peer Collaborative Engagements
- 500 Domain Expert Insights (With Name, Company, and Date)
- 150,000 Data Room Credits
- Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
- Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
- Use Your Own Data and MarketGlassTM Data Room Content.
- My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
- Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges
HIGHLIGHTS & REPORT INDEX
What`s New?
» Special discussions on the global economic climate and market sentiment
» Coverage on global competitiveness and key competitor percentage market shares
» Market presence analysis across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass™ research platform
» Complimentary updates for one year
» Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes
Economic Outlook
The global economic outlook is improving, and growth recovery, albeit on the lower side, is expected for this year and the next. The United States although witnessing slowing GDP growth in response to tight monetary and financial conditions, has nevertheless overcome the recession threat. Easing of headline inflation in Euro area is helping boost real incomes and is contributing to pick-up in economic activity. China is expected to see strong increases in GDP in the coming year as the pandemic threat recedes and the government sheds its zero-COVID policy. With optimistic GDP projections, India remains on-course to emerge into a US$6 trillion economy by 2030, surpassing Japan and Germany.
The upturn, however, remains fragile and a number of interlocking challenges continue to run in parallel, such as continued uncertainty around the war in Ukraine; slower than expected decline in global headline inflation; continuation of food and fuel inflation as a persistent economic problem for most developing countries; and still high retail inflation and its impact on consumer confidence and spending. Countries and their governments are showing signs of weathering these challenges, which helps lift market sentiments. As governments continue to combat inflation to get it down to more economically conformable levels by raising interest rates, new job creation will slowdown and impact economic activity. Stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced.
Although corporate investments can likely be held back by inflation worries and weaker demand, rise of new technologies will reverse partially this prevailing investment sentiment. Rise of generative AI; applied AI; industrializing machine learning; next-generation software development; Web3; cloud and edge computing; quantum technologies; electrification and renewables and climate technologies beyond electrification and renewables, will open up the global investment landscape. The technologies hold the potential to drive sizeable incremental growth and value to global GDP in the coming years. The short-term is expected to be a mixed bag of challenges and opportunities for both consumers and investors alike. There is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Global Genetic Testing Market to Reach $24.8 Billion by 2030
The global market for Genetic Testing estimated at US$12 Billion in the year 2022, is projected to reach a revised size of US$24.8 Billion by 2030, growing at aCAGR of 9.5% over the period 2022-2030. Prenatal & Newborn, one of the segments analyzed in the report, is projected to record 9.7% CAGR and reach US$8.4 Billion by the end of the analysis period. Growth in the Diagnostic segment is estimated at 9% CAGR for the next 8-year period.
The U.S. Market is Estimated at $5.1 Billion, While China is Forecast to Grow at 11.7% CAGR
The Genetic Testing market in the U.S. is estimated at US$5.1 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$2 Billion by the year 2030 trailing a CAGR of 11.7% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8% and 9.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 8.2% CAGR.
SELECT PLAYERS
Agilent Technologies, Inc.; Asuragen, Inc.; Biocartis NV; Agena Bioscience, Inc.; ARUP Laboratories; Bioiberica SAU; AutoGenomics, Inc.; Biodesix, Inc.; Admera Health; Annoroad Gene Technology; Berry Genomics Co., Ltd.; Ariel Precision Medicine, Inc.; AlphaBiolabs Ltd. ; AnchorDx; Alexian Brothers of America, Inc.
SEGMENTS
» Type (Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic, Other Types) » Application (Cancer, Genetic Disease, Cardiovascular Disease, Other Applications)
GEOGRAPHIES
» World » USA » Canada » Japan » China » Europe » France » Germany » Italy » UK » Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Impact of Covid-19 and a Looming Global Recession |
| Genetic Testing – Global Key Competitors Percentage Market Share in 2021 (E) |
| Competitive Market Presence - Strong/Active/Niche/Trivial for 249 Players Worldwide in 2021 (E) |
| A Prelude to Genetic Testing |
| Top Ten Genetic Diseases Worldwide |
| Different Types of Genetic Tests include |
| Prenatal and Newborn Screening |
| Diagnostic Testing |
| Predictive & Presymptomatic Testing |
| Carrier Identification |
| Pharmacogenomic Testing |
| List of Genetic Disorders by Event, Genetic Manifestation and Prevalence |
| Genetic Testing Delivery Models |
| Genetic Sequencing Approaches |
| Genetic Testing Market Witnesses Sluggish Growth during COVID-19, Set to Record Exponential Growth Post-COVID |
| Expanding Applications to Drive Genetic Testing Market |
| Regional Landscape |
| Prenatal Testing Market to Rise |
| Market Outlook |
| 2. FOCUS ON SELECT PLAYERS |
| Recent Market Activity |
| World Brands |
| Innovations |
| 3. MARKET TRENDS & DRIVERS |
| Studies Indicate Possible Correlation between Genetic Variations Tied to Immunity and COVID-19 Severity |
| SEGMENT ANALYSIS |
| Prenatal Testing – Changing the World of Pregnancy Care |
| List of Available Prenatal Screening and Diagnostic Tests by Indication |
| Players in the Prenatal and New Born Genetic Testing Market |
| Conventional Invasive Pre-Natal Diagnostic Techniques – A Risky Affair |
| Emergence of Non-Invasive Prenatal Diagnosis (NIPD) |
| Competition Intensifies in the NIPD Market |
| Strain on Resources Prevent Wide Adoption of Expanded Carrier Sequencing |
| Predictive Diagnostics |
| Breast Cancer Gene Testing Market to Expand Strongly |
| Myriad Genetics – A Leader in Breast Cancer Testing |
| Discovery of Novel Biomarkers Crucial to Predictive Diagnostics |
| Pharmacogenomics Development Augurs Growth of Genetic Testing Market |
| MARKET TRENDS AND GROWTH DRIVERS |
| Genetic Testing Paves the Way for Personalized Medicine |
| TABLE 1: Drug Ineffectiveness for Select Therapeutic Categories - Necessitating Personalized Medic |
| Next-Generation Sequencing (NGS) – A Giant Leap in Genome Sequencing |
| Biomarker Discovery Leads to Advanced Genetic Testing |
| Select List of Available Tumor Markers |
| Immense Popularity of Ancestry Testing |
| Increasing Focus on Data Churning |
| Genetic Testing to Explode into Provider Workflow with Intriguing Use Cases |
| Primary Factors Responsible for Waning Interest in Direct-to Consumer Genetic Testing |
| Liquid Biopsy to Facilitate Cancer Diagnosis and Treatment |
| Hybrid Labs to Bridge Gap Between Traditional and DTC Models |
| Rising Prevalence of Cancer and Chromosomal Disorders Augments Demand for Cell-Free DNA Testing |
| Emergence of Rapid DNA Testing |
| Oncology – A Key Focus Area for Genetic Testing |
| EXHIBIT 1: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 |
| Ageing Demographics to Drive Demand for Genetic Testing |
| EXHIBIT 12: Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030 |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Recent Past, Current & Future Analysis for Genetic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
| World Historic Review for Genetic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| World 16-Year Perspective for Genetic Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030 |
| World Recent Past, Current & Future Analysis for Prenatal & Newborn by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
| World Historic Review for Prenatal & Newborn by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| World 16-Year Perspective for Prenatal & Newborn by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030 |
| World Recent Past, Current & Future Analysis for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
| World Historic Review for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| World 16-Year Perspective for Diagnostic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030 |
| World Recent Past, Current & Future Analysis for Predictive & Presymptomatic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
| World Historic Review for Predictive & Presymptomatic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| World 16-Year Perspective for Predictive & Presymptomatic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030 |
| World Recent Past, Current & Future Analysis for Carrier by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
| World Historic Review for Carrier by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| World 16-Year Perspective for Carrier by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030 |
| World Recent Past, Current & Future Analysis for Pharmacogenomic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
| World Historic Review for Pharmacogenomic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| World 16-Year Perspective for Pharmacogenomic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030 |
| World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
| World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030 |
| World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
| World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| World 16-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030 |
| World Recent Past, Current & Future Analysis for Genetic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
| World Historic Review for Genetic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| World 16-Year Perspective for Genetic Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030 |
| World Recent Past, Current & Future Analysis for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
| World Historic Review for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| World 16-Year Perspective for Cardiovascular Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030 |
| World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
| World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030 |
| World Genetic Testing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E) |
| Use of Genomic Data in Clinical Settings to Gather Pace |
| The United States: Leading Market for Genetic Testing Globally |
| Predictive Screening: Another Growth Area |
| Growing Relevance of Personalized Medicine Augurs Well |
| Rising Incidence of Cancer in the US: Driver for Cancer Genetic Testing |
| Estimated Number of New Cancer Cases and Deaths in the US (2019) |
| Newborn Testing Gains Ground |
| Invasive Prenatal Diagnosis Gives Way to Non-Invasive Prenatal Testing |
| Coverage of NIPT in Average Risk Pregnancies Expands Target Market |
| Direct-to-Consumer Testing: A Growing Market |
| Favorable Reimbursement Policies |
| Favorable Insurance Coverage for Cystic Fibrosis Genetic Testing |
| Demographic Changes Offer Growth Opportunities |
| TABLE 14: North American Aging Population by Age Group: 1975-2050 |
| Skepticism Limits Widespread Adoption of Genetic Testing |
| Competitive Overview |
| Myriad Eyes Diversification and Expansion for Growth |
| Natera Holds Fort in the NIPT Market |
| Invitae Banks on Low Cost Solutions for Expanding Revenues |
| Regulatory Environment |
| Genetic Information Nondiscrimination Act Boosts Genetic Testing |
| Stricter Regulations for DTC Genetic Testing |
| FDA Attempts to Put a Leash around Unapproved DTC Genetic Tests |
| Select Genetic Test Reimbursement Codes |
| Market Analytics |
| USA Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
| USA Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| USA 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2023 & 2030 |
| USA Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
| USA Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| USA 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2023 & 2030 |
| CANADA |
| Rising Incidence of Chronic Diseases Spurs Genetic Testing Demand |
| Number of New Cancer Cases in Canada: 2019 |
| Regulatory Scenario |
| Market Analytics |
| Canada Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
| Canada Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| Canada 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2023 & 2030 |
| Canada Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
| Canada Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| Canada 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2023 & 2030 |
| JAPAN |
| Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E) |
| Demographics Drive Market Growth |
| DTC Genetic Testing Regulatory Scenario |
| Japan Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
| Japan Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| Japan 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2023 & 2030 |
| Japan Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
| Japan Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| Japan 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2023 & 2030 |
| CHINA |
| Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E) |
| Market Overview |
| China Attracts Domestic and Foreign Players |
| Strong Focus on Genomics |
| Genetic Testing to Reveal Real Talent in Children – A New Popular Application |
| China to Take Lead in Rapidly Growing Asian Genomics Market |
| Market Analytics |
| China Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
| China Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| China 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2023 & 2030 |
| China Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
| China Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| China 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2023 & 2030 |
| EUROPE |
| Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E) |
| European Personalized Medicine Market to Exhibit Robust Growth |
| Aging Population to Drive Demand for Genetic Testing |
| TABLE 28: European Population by Age Group (2016, 2030 & 2050): Percentage Share Breakdown by Age Group for 0-14, 15-64, and 65 & Above |
| Legislations/Regulatory Policies in Select European Countries |
| Legislations Governing Genetic Testing in Select European Countries |
| Rising Cancer Incidence Augurs Well for European Genetic Testing Market |
| Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for 2018 |
| Europe Recent Past, Current & Future Analysis for Genetic Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
| Europe Historic Review for Genetic Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| Europe 16-Year Perspective for Genetic Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030 |
| Europe Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
| Europe Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| Europe 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2023 & 2030 |
| Europe Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
| Europe Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| Europe 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2023 & 2030 |
| FRANCE |
| Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E) |
| France Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
| France Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| France 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2023 & 2030 |
| France Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
| France Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| France 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2023 & 2030 |
| GERMANY |
| Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E) |
| Parliamentary Regulations |
| Germany Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
| Germany Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| Germany 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2023 & 2030 |
| Germany Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
| Germany Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| Germany 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2023 & 2030 |
| ITALY |
| Italy Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
| Italy Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| Italy 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2023 & 2030 |
| Italy Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
| Italy Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| Italy 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2023 & 2030 |
| UNITED KINGDOM |
| Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E) |
| Increased Support for Personalized Medicine to Drive Genetic Testing |
| SMIP for Pharmacogenomic Testing |
| Increasing Need for Less Risky Prenatal Diagnostic Methods in the UK |
| Principles for DTC Genetic Testing Laid out by HGC |
| UK Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
| UK Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| UK 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2023 & 2030 |
| UK Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
| UK Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| UK 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2023 & 2030 |
| REST OF EUROPE |
| Rest of Europe Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
| Rest of Europe Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| Rest of Europe 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2023 & 2030 |
| Rest of Europe Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
| Rest of Europe Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| Rest of Europe 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2023 & 2030 |
| ASIA-PACIFIC |
| Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E) |
| Healthcare Spending in Asia-Pacific: On the Rise |
| India |
| Australia and New Zealand |
| Market Analytics |
| Asia-Pacific Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
| Asia-Pacific Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| Asia-Pacific 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2023 & 2030 |
| Asia-Pacific Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
| Asia-Pacific Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| Asia-Pacific 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2023 & 2030 |
| REST OF WORLD |
| Predictive Screening: Another Growth Area |
| Market Analytics |
| Rest of World Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
| Rest of World Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| Rest of World 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2023 & 2030 |
| Rest of World Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
| Rest of World Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
| Rest of World 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2023 & 2030 |
| IV. COMPETITION |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com
DIFFERENTIATORS
Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .
What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).
WHAT SETS US APART
FULL STACK DATA ACCESS
- Primary Research Cluster Data
- Influencer Engagement Stats
- Evidence of Primary Research
- List of Companies Engaged
- Hundreds of Pages of Research
- Peer Collaborative Interactions
- Enterprise Data Exchanges
- MarketGlassTM Platform Insider
- Geographic Pricing Dynamics
- Competitive Shares by Country
- Brand Curation & Insights
- Domain Expert Pool
Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.
Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.
Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.
Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.
Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.
Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.
Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.
Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.
No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.